Arbutus Biopharma
ABUS
49 hedge funds and large institutions have $73.1M invested in Arbutus Biopharma in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 10 closing their positions.
40% more call options, than puts
Call options by funds: $517K | Put options by funds: $368K
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
4% less funds holding
Funds holding: 51 → 49 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
11% less capital invested
Capital invested by funds: $81.7M → $73.1M (-$8.68M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$3.28M |
| 2 |
B
Bailard
Foster City,
California
|
+$768K |
| 3 |
DCM
Dialectic Capital Management
Norwalk,
Connecticut
|
+$714K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$705K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$412K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.73M |
| 2 |
Millennium Management
New York
|
-$1.45M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$571K |
| 5 |
TI
Telemetry Investments
New York
|
-$449K |
ABUS Hedge Fund Activity: Q1 2016 in Review
49 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2016, worth a combined $73.1M — down 11% from $81.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ABUS and 9 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 14 added.
The largest buyer was Primecap Management, adding an estimated $3.28M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.73M sold.
- 49 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2016, down from 51 in Q4 2015.
- Funds reported $73.1M of Arbutus Biopharma stock for Q1 2016, down 11% quarter-over-quarter.
- 9 funds opened new Arbutus Biopharma positions in Q1 2016 and 10 closed out, a net change of -1 holder.
- The largest Arbutus Biopharma buyer in Q1 2016 was Primecap Management, an estimated $3.28M added.
- The largest Arbutus Biopharma seller in Q1 2016 was Franklin Resources, an estimated $5.73M sold.
Based on aggregated 13F filings for Q1 2016.